NCT05607550Phase 3Active not recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Study sponsor: ArriVent BioPharma, Inc. · AVBP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10-06Actual
Enrollment · participants398Actual
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 15 Aug 2025. After: 6 Oct 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview